fbpx

Immunotherapy Car-T cells

Immunotherapy CAR T stands for Chimeric Antigen Receptor T-cell therapy, which is a form of immunotherapy. With CAR T therapy, your immune system’s T cells are modified to recognize and destroy cancer cells. CAR T therapy is an option if your primary and secondary treatments failed to eliminate your cancer, or if your cancer has returned after these treatments. Before receiving CAR T therapy, you will undergo low-dose chemotherapy in order to prepare for treatment. CAR T may also be an option for patients not eligible to receive a stem cell transplant.

The Concept of a  “Living Drug”. How does it Work?

CAR T cells are the equivalent of “giving patients a “living drug” As its name implies, the backbone of CAR T-cell therapy is T cells, which are often called the workhorses of the immune system because of their critical role in orchestrating the immune response and killing cells infected by pathogens. The therapy requires drawing blood from patients and separating out the T cells. Next, using a disarmed virus, the T cells are genetically engineered to produce receptors on their surface called chimeric antigen receptors, or CARs.

These receptors are synthetic molecules, they don’t exist naturally. These special receptors allow the T cells to recognize and attach to a specific protein, or antigen, on tumor cells. The CAR T cell therapies furthest along in development target an antigen found on B cells called CD19.

Once the collected T cells have been engineered to express the antigen-specific CAR, they are “expanded” in the laboratory into the hundreds of millions.

The final step is the infusion of the CAR T cells into the patient (which is preceded by a “lymphodepleting” chemotherapy regimen. If all goes as planned, the engineered cells further multiply in the patient’s body and, with guidance from their engineered receptor, recognize and kill cancer cells that harbor the antigen on their surfaces.

The Concept of a  “Living Drug”. How does it Work?

CAR T cells are the equivalent of “giving patients a “living drug” As its name implies, the backbone of CAR T-cell therapy is T cells, which are often called the workhorses of the immune system because of their critical role in orchestrating the immune response and killing cells infected by pathogens. The therapy requires drawing blood from patients and separating out the T cells. Next, using a disarmed virus, the T cells are genetically engineered to produce receptors on their surface called chimeric antigen receptors, or CARs.

These receptors are synthetic molecules, they don’t exist naturally. These special receptors allow the T cells to recognize and attach to a specific protein, or antigen, on tumor cells. The CAR T cell therapies furthest along in development target an antigen found on B cells called CD19.

Once the collected T cells have been engineered to express the antigen-specific CAR, they are “expanded” in the laboratory into the hundreds of millions.

The final step is the infusion of the CAR T cells into the patient (which is preceded by a “lymphodepleting” chemotherapy regimen. If all goes as planned, the engineered cells further multiply in the patient’s body and, with guidance from their engineered receptor, recognize and kill cancer cells that harbor the antigen on their surfaces.

We help you Enhance your own body’s ability to fight, repair and restore through Advanced Regenerative Medicine therapies.

Considerations for Patient Selection

CAR T cell therapy is a novel treatment approach,  it is generally an autologous cell therapy that may have different patient selection considerations than autologous stem cell transplant (ASCT); some examples include prior lines of therapy, upper age limit, severity of comorbidities, and chemoresistance status.

Patient selection may be based on adequate organ function and physiological reserve. A patient’s ability to tolerate fever and other potentially severe symptoms, such as cytokine release syndrome (CRS) and neurologic toxicity (NT) associated with CAR T cell therapy, should be determined.

Cash based procedure and ability to travel to an authorized treatment center, as well as having an adequate patient support network are key considerations. CAR T cell therapy is an involved process, making it necessary for patients to have competent and committed caregiver support.Patients will be required to remain within close proximity to the center throughout the process and for a period of time after receiving CAR T cell therapy to monitor for adverse reactions.

Considerations for Patient Selection

CAR T cell therapy is a novel treatment approach,  it is generally an autologous cell therapy that may have different patient selection considerations than autologous stem cell transplant (ASCT); some examples include prior lines of therapy, upper age limit, severity of comorbidities, and chemoresistance status.

Patient selection may be based on adequate organ function and physiological reserve. A patient’s ability to tolerate fever and other potentially severe symptoms, such as cytokine release syndrome (CRS) and neurologic toxicity (NT) associated with CAR T cell therapy, should be determined.

Cash based procedure and ability to travel to an authorized treatment center, as well as having an adequate patient support network are key considerations. CAR T cell therapy is an involved process, making it necessary for patients to have competent and committed caregiver support.Patients will be required to remain within close proximity to the center throughout the process and for a period of time after receiving CAR T cell therapy to monitor for adverse reactions.

0

Years of Service

0

Assisted Patients

0

Years of Service

0

Assisted Patients

Contact Us to discuss your treatment at Cellular Hope Institute

Cellular Hope Institute – Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305 560 5337

info@cellularhopeinstitute.com

Fill out this field
Fill out this field
Fill out this field
Fill out this field
Fill out this field
Fill out this field

Contact Us to discuss your treatment at Cellular Hope Institute

Cellular Hope Institute – Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305 560 5337

info@cellularhopeinstitute.com

Fill out this field
Fill out this field
Fill out this field
Fill out this field
Fill out this field
Fill out this field
Menu